APO Research
Talk to an analyst

APO RESEARCH · REPORT

NGS Tumor Gene Analysis Software

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global NGS Tumor Gene Analysis Software Market Outlook and Growth Opportunities 2026

4 July 2026199 pages

Choose your research edition.

Industry ResearchNGS Tumor Gene Analysis Software Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal NGS Tumor Gene Analysis Software Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal NGS Tumor Gene Analysis Software Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal NGS Tumor Gene Analysis Software Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal NGS Tumor Gene Analysis Software Market Analysis and Forecast 2026-2032173 pages · $4,950 USD

Market perspective

The global NGS Tumor Gene Analysis Software market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for NGS Tumor Gene Analysis Software is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for NGS Tumor Gene Analysis Software is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for NGS Tumor Gene Analysis Software is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the NGS Tumor Gene Analysis Software market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the NGS Tumor Gene Analysis Software market include Roche, Illumina, Thermo Fisher Scientific, BGI Group, Novogene, Geneseeq, AmoyDx, Burning Rock Medicine and GTH.O, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global NGS Tumor Gene Analysis Software market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of NGS Tumor Gene Analysis Software and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents NGS Tumor Gene Analysis Software revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global NGS Tumor Gene Analysis Software market.

NGS Tumor Gene Analysis Software Segment by Company

Roche

Illumina

Thermo Fisher Scientific

BGI Group

Novogene

Geneseeq

AmoyDx

Burning Rock Medicine

GTH.O

Golden Helix, Inc

Diatech Pharmacogenetics

ViennaLab Diagnostics GmbH

3D Medicines

NGS Tumor Gene Analysis Software Segment by Type

Non-Small Cell Lung Cancer

Human 6 Gene Mutations

Human 12 Gene Mutations

Other

NGS Tumor Gene Analysis Software Segment by Application

Hospitals and Health Systems

Research Institute

Other

NGS Tumor Gene Analysis Software Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global NGS Tumor Gene Analysis Software status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the NGS Tumor Gene Analysis Software key companies, revenue, market share, and recent developments.

3. To split the NGS Tumor Gene Analysis Software breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions NGS Tumor Gene Analysis Software market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify NGS Tumor Gene Analysis Software significant trends, drivers, influence factors in global and regions.

6. To analyze NGS Tumor Gene Analysis Software competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NGS Tumor Gene Analysis Software market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of NGS Tumor Gene Analysis Software and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NGS Tumor Gene Analysis Software.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global NGS Tumor Gene Analysis Software industry.

Chapter 3: Detailed analysis of NGS Tumor Gene Analysis Software company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of NGS Tumor Gene Analysis Software in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of NGS Tumor Gene Analysis Software in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. NGS Tumor Gene Analysis Software Industry Trends Table 2. NGS Tumor Gene Analysis Software Industry Drivers Table 3. NGS Tumor Gene Analysis Software Industry Opportunities and Challenges Table 4. NGS Tumor Gene Analysis Software Industry Restraints Table 5. Global NGS Tumor Gene Analysis Software Revenue by Company (US$ Million) & (2021-2026) Table 6. Global NGS Tumor Gene Analysis Software Revenue Share by Company (2021-2026) Table 7. Global NGS Tumor Gene Analysis Software Company Ranking, (2024-2026) & (US$ Million) Table 8. Global NGS Tumor Gene Analysis Software Key Company Manufacturing Base & Headquarters Table 9. Global NGS Tumor Gene Analysis Software Company, Product Type & Application Table 10. Global NGS Tumor Gene Analysis Software Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global NGS Tumor Gene Analysis Software by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Non-Small Cell Lung Cancer Table 15. Significant Companies of Human 6 Gene Mutations Table 16. Significant Companies of Human 12 Gene Mutations Table 17. Significant Companies of Other Table 18. Global NGS Tumor Gene Analysis Software Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global NGS Tumor Gene Analysis Software Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global NGS Tumor Gene Analysis Software Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global NGS Tumor Gene Analysis Software Sales Value Share by Type (2021-2026) Table 22. Global NGS Tumor Gene Analysis Software Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospitals and Health Systems Table 24. Significant Companies of Research Institute Table 25. Significant Companies of Other Table 26. Global NGS Tumor Gene Analysis Software Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global NGS Tumor Gene Analysis Software Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global NGS Tumor Gene Analysis Software Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global NGS Tumor Gene Analysis Software Sales Value Share by Application (2021-2026) Table 30. Global NGS Tumor Gene Analysis Software Sales Value Share by Application (2027-2032) Table 31. Global NGS Tumor Gene Analysis Software Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global NGS Tumor Gene Analysis Software Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global NGS Tumor Gene Analysis Software Sales Value Share by Region (2021-2026) Table 34. Global NGS Tumor Gene Analysis Software Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global NGS Tumor Gene Analysis Software Sales Value Share by Region (2027-2032) Table 36. Global NGS Tumor Gene Analysis Software Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global NGS Tumor Gene Analysis Software Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global NGS Tumor Gene Analysis Software Sales Value Market Share by Country (2021-2026) Table 39. Global NGS Tumor Gene Analysis Software Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global NGS Tumor Gene Analysis Software Sales Value Market Share by Country (2027-2032) Table 41. Roche Company Information Table 42. Roche Business Overview Table 43. Roche NGS Tumor Gene Analysis Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Roche NGS Tumor Gene Analysis Software Product Portfolio Table 45. Roche Recent Development Table 46. Illumina Company Information Table 47. Illumina Business Overview Table 48. Illumina NGS Tumor Gene Analysis Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Illumina NGS Tumor Gene Analysis Software Product Portfolio Table 50. Illumina Recent Development Table 51. Thermo Fisher Scientific Company Information Table 52. Thermo Fisher Scientific Business Overview Table 53. Thermo Fisher Scientific NGS Tumor Gene Analysis Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Thermo Fisher Scientific NGS Tumor Gene Analysis Software Product Portfolio Table 55. Thermo Fisher Scientific Recent Development Table 56. BGI Group Company Information Table 57. BGI Group Business Overview Table 58. BGI Group NGS Tumor Gene Analysis Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. BGI Group NGS Tumor Gene Analysis Software Product Portfolio Table 60. BGI Group Recent Development Table 61. Novogene Company Information Table 62. Novogene Business Overview Table 63. Novogene NGS Tumor Gene Analysis Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Novogene NGS Tumor Gene Analysis Software Product Portfolio Table 65. Novogene Recent Development Table 66. Geneseeq Company Information Table 67. Geneseeq Business Overview Table 68. Geneseeq NGS Tumor Gene Analysis Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Geneseeq NGS Tumor Gene Analysis Software Product Portfolio Table 70. Geneseeq Recent Development Table 71. AmoyDx Company Information Table 72. AmoyDx Business Overview Table 73. AmoyDx NGS Tumor Gene Analysis Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. AmoyDx NGS Tumor Gene Analysis Software Product Portfolio Table 75. AmoyDx Recent Development Table 76. Burning Rock Medicine Company Information Table 77. Burning Rock Medicine Business Overview Table 78. Burning Rock Medicine NGS Tumor Gene Analysis Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Burning Rock Medicine NGS Tumor Gene Analysis Software Product Portfolio Table 80. Burning Rock Medicine Recent Development Table 81. GTH.O Company Information Table 82. GTH.O Business Overview Table 83. GTH.O NGS Tumor Gene Analysis Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. GTH.O NGS Tumor Gene Analysis Software Product Portfolio Table 85. GTH.O Recent Development Table 86. Golden Helix, Inc Company Information Table 87. Golden Helix, Inc Business Overview Table 88. Golden Helix, Inc NGS Tumor Gene Analysis Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Golden Helix, Inc NGS Tumor Gene Analysis Software Product Portfolio Table 90. Golden Helix, Inc Recent Development Table 91. Diatech Pharmacogenetics Company Information Table 92. Diatech Pharmacogenetics Business Overview Table 93. Diatech Pharmacogenetics NGS Tumor Gene Analysis Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Diatech Pharmacogenetics NGS Tumor Gene Analysis Software Product Portfolio Table 95. Diatech Pharmacogenetics Recent Development Table 96. ViennaLab Diagnostics GmbH Company Information Table 97. ViennaLab Diagnostics GmbH Business Overview Table 98. ViennaLab Diagnostics GmbH NGS Tumor Gene Analysis Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. ViennaLab Diagnostics GmbH NGS Tumor Gene Analysis Software Product Portfolio Table 100. ViennaLab Diagnostics GmbH Recent Development Table 101. 3D Medicines Company Information Table 102. 3D Medicines Business Overview Table 103. 3D Medicines NGS Tumor Gene Analysis Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. 3D Medicines NGS Tumor Gene Analysis Software Product Portfolio Table 105. 3D Medicines Recent Development Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. NGS Tumor Gene Analysis Software Product Image Figure 2. Global NGS Tumor Gene Analysis Software Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global NGS Tumor Gene Analysis Software Market Size (2021-2032) & (US$ Million) Figure 4. Global NGS Tumor Gene Analysis Software Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Non-Small Cell Lung Cancer Image Figure 8. Human 6 Gene Mutations Image Figure 9. Human 12 Gene Mutations Image Figure 10. Other Image Figure 11. Global NGS Tumor Gene Analysis Software Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global NGS Tumor Gene Analysis Software Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global NGS Tumor Gene Analysis Software Sales Value Share by Type (2021-2032) Figure 14. Hospitals and Health Systems Image Figure 15. Research Institute Image Figure 16. Other Image Figure 17. Global NGS Tumor Gene Analysis Software Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global NGS Tumor Gene Analysis Software Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global NGS Tumor Gene Analysis Software Sales Value Share by Application (2021-2032) Figure 20. Global NGS Tumor Gene Analysis Software Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global NGS Tumor Gene Analysis Software Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America NGS Tumor Gene Analysis Software Sales Value (2021-2032) & (US$ Million) Figure 23. North America NGS Tumor Gene Analysis Software Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe NGS Tumor Gene Analysis Software Sales Value (2021-2032) & (US$ Million) Figure 25. Europe NGS Tumor Gene Analysis Software Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific NGS Tumor Gene Analysis Software Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific NGS Tumor Gene Analysis Software Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America NGS Tumor Gene Analysis Software Sales Value (2021-2032) & (US$ Million) Figure 29. South America NGS Tumor Gene Analysis Software Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa NGS Tumor Gene Analysis Software Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa NGS Tumor Gene Analysis Software Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Non-Small Cell Lung Cancer
  • Human 6 Gene Mutations
  • Human 12 Gene Mutations
  • Other
Applications
  • Hospitals and Health Systems
  • Research Institute
  • Other
Companies covered
  • Roche
  • Illumina
  • Thermo Fisher Scientific
  • BGI Group
  • Novogene
  • Geneseeq
  • AmoyDx
  • Burning Rock Medicine
  • GTH.O
  • Golden Helix, Inc
  • Diatech Pharmacogenetics
  • ViennaLab Diagnostics GmbH
  • 3D Medicines

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global NGS Tumor Gene Analysis Software Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global NGS Tumor Gene Analysis Software Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 NGS Tumor Gene Analysis Software Market Dynamics
  1. 2.1 NGS Tumor Gene Analysis Software Industry Trends
  2. 2.2 NGS Tumor Gene Analysis Software Industry Drivers
  3. 2.3 NGS Tumor Gene Analysis Software Industry Opportunities and Challenges
  4. 2.4 NGS Tumor Gene Analysis Software Industry Restraints
3 NGS Tumor Gene Analysis Software Market by Company
  1. 3.1 Global NGS Tumor Gene Analysis Software Company Revenue Ranking in 2025
  2. 3.2 Global NGS Tumor Gene Analysis Software Revenue by Company (2021-2026)
  3. 3.3 Global NGS Tumor Gene Analysis Software Company Ranking (2024-2026)
  4. 3.4 Global NGS Tumor Gene Analysis Software Company Manufacturing Base and Headquarters
  5. 3.5 Global NGS Tumor Gene Analysis Software Company Product Type and Application
  6. 3.6 Global NGS Tumor Gene Analysis Software Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global NGS Tumor Gene Analysis Software Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 NGS Tumor Gene Analysis Software Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 NGS Tumor Gene Analysis Software Market by Type
  1. 4.1 NGS Tumor Gene Analysis Software Type Introduction
  2. 4.1.1 Non-Small Cell Lung Cancer
  3. 4.1.2 Human 6 Gene Mutations
  4. 4.1.3 Human 12 Gene Mutations
  5. 4.1.4 Other
  6. 4.2 Global NGS Tumor Gene Analysis Software Sales Value by Type
  7. 4.2.1 Global NGS Tumor Gene Analysis Software Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global NGS Tumor Gene Analysis Software Sales Value by Type (2021-2032)
  9. 4.2.3 Global NGS Tumor Gene Analysis Software Sales Value Share by Type (2021-2032)
5 NGS Tumor Gene Analysis Software Market by Application
  1. 5.1 NGS Tumor Gene Analysis Software Application Introduction
  2. 5.1.1 Hospitals and Health Systems
  3. 5.1.2 Research Institute
  4. 5.1.3 Other
  5. 5.2 Global NGS Tumor Gene Analysis Software Sales Value by Application
  6. 5.2.1 Global NGS Tumor Gene Analysis Software Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global NGS Tumor Gene Analysis Software Sales Value by Application (2021-2032)
  8. 5.2.3 Global NGS Tumor Gene Analysis Software Sales Value Share by Application (2021-2032)
6 NGS Tumor Gene Analysis Software Regional Value Analysis
  1. 6.1 Global NGS Tumor Gene Analysis Software Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global NGS Tumor Gene Analysis Software Sales Value by Region (2021-2032)
  3. 6.2.1 Global NGS Tumor Gene Analysis Software Sales Value by Region: 2021-2026
  4. 6.2.2 Global NGS Tumor Gene Analysis Software Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America NGS Tumor Gene Analysis Software Sales Value (2021-2032)
  7. 6.3.2 North America NGS Tumor Gene Analysis Software Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe NGS Tumor Gene Analysis Software Sales Value (2021-2032)
  10. 6.4.2 Europe NGS Tumor Gene Analysis Software Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific NGS Tumor Gene Analysis Software Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific NGS Tumor Gene Analysis Software Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America NGS Tumor Gene Analysis Software Sales Value (2021-2032)
  16. 6.6.2 South America NGS Tumor Gene Analysis Software Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa NGS Tumor Gene Analysis Software Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa NGS Tumor Gene Analysis Software Sales Value Share by Country, 2025 VS 2032
7 NGS Tumor Gene Analysis Software Country-level Value Analysis
  1. 7.1 Global NGS Tumor Gene Analysis Software Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global NGS Tumor Gene Analysis Software Sales Value by Country (2021-2032)
  3. 7.2.1 Global NGS Tumor Gene Analysis Software Sales Value by Country (2021-2026)
  4. 7.2.2 Global NGS Tumor Gene Analysis Software Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt NGS Tumor Gene Analysis Software Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt NGS Tumor Gene Analysis Software Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt NGS Tumor Gene Analysis Software Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Roche
  2. 8.1.1 Roche Company Information
  3. 8.1.2 Roche Business Overview
  4. 8.1.3 Roche NGS Tumor Gene Analysis Software Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Roche NGS Tumor Gene Analysis Software Product Portfolio
  6. 8.1.5 Roche Recent Developments
  7. 8.2 Illumina
  8. 8.2.1 Illumina Company Information
  9. 8.2.2 Illumina Business Overview
  10. 8.2.3 Illumina NGS Tumor Gene Analysis Software Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Illumina NGS Tumor Gene Analysis Software Product Portfolio
  12. 8.2.5 Illumina Recent Developments
  13. 8.3 Thermo Fisher Scientific
  14. 8.3.1 Thermo Fisher Scientific Company Information
  15. 8.3.2 Thermo Fisher Scientific Business Overview
  16. 8.3.3 Thermo Fisher Scientific NGS Tumor Gene Analysis Software Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Thermo Fisher Scientific NGS Tumor Gene Analysis Software Product Portfolio
  18. 8.3.5 Thermo Fisher Scientific Recent Developments
  19. 8.4 BGI Group
  20. 8.4.1 BGI Group Company Information
  21. 8.4.2 BGI Group Business Overview
  22. 8.4.3 BGI Group NGS Tumor Gene Analysis Software Revenue and Gross Margin (2021-2026)
  23. 8.4.4 BGI Group NGS Tumor Gene Analysis Software Product Portfolio
  24. 8.4.5 BGI Group Recent Developments
  25. 8.5 Novogene
  26. 8.5.1 Novogene Company Information
  27. 8.5.2 Novogene Business Overview
  28. 8.5.3 Novogene NGS Tumor Gene Analysis Software Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novogene NGS Tumor Gene Analysis Software Product Portfolio
  30. 8.5.5 Novogene Recent Developments
  31. 8.6 Geneseeq
  32. 8.6.1 Geneseeq Company Information
  33. 8.6.2 Geneseeq Business Overview
  34. 8.6.3 Geneseeq NGS Tumor Gene Analysis Software Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Geneseeq NGS Tumor Gene Analysis Software Product Portfolio
  36. 8.6.5 Geneseeq Recent Developments
  37. 8.7 AmoyDx
  38. 8.7.1 AmoyDx Company Information
  39. 8.7.2 AmoyDx Business Overview
  40. 8.7.3 AmoyDx NGS Tumor Gene Analysis Software Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AmoyDx NGS Tumor Gene Analysis Software Product Portfolio
  42. 8.7.5 AmoyDx Recent Developments
  43. 8.8 Burning Rock Medicine
  44. 8.8.1 Burning Rock Medicine Company Information
  45. 8.8.2 Burning Rock Medicine Business Overview
  46. 8.8.3 Burning Rock Medicine NGS Tumor Gene Analysis Software Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Burning Rock Medicine NGS Tumor Gene Analysis Software Product Portfolio
  48. 8.8.5 Burning Rock Medicine Recent Developments
  49. 8.9 GTH.O
  50. 8.9.1 GTH.O Company Information
  51. 8.9.2 GTH.O Business Overview
  52. 8.9.3 GTH.O NGS Tumor Gene Analysis Software Revenue and Gross Margin (2021-2026)
  53. 8.9.4 GTH.O NGS Tumor Gene Analysis Software Product Portfolio
  54. 8.9.5 GTH.O Recent Developments
  55. 8.10 Golden Helix, Inc
  56. 8.10.1 Golden Helix, Inc Company Information
  57. 8.10.2 Golden Helix, Inc Business Overview
  58. 8.10.3 Golden Helix, Inc NGS Tumor Gene Analysis Software Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Golden Helix, Inc NGS Tumor Gene Analysis Software Product Portfolio
  60. 8.10.5 Golden Helix, Inc Recent Developments
  61. 8.11 Diatech Pharmacogenetics
  62. 8.11.1 Diatech Pharmacogenetics Company Information
  63. 8.11.2 Diatech Pharmacogenetics Business Overview
  64. 8.11.3 Diatech Pharmacogenetics NGS Tumor Gene Analysis Software Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Diatech Pharmacogenetics NGS Tumor Gene Analysis Software Product Portfolio
  66. 8.11.5 Diatech Pharmacogenetics Recent Developments
  67. 8.12 ViennaLab Diagnostics GmbH
  68. 8.12.1 ViennaLab Diagnostics GmbH Company Information
  69. 8.12.2 ViennaLab Diagnostics GmbH Business Overview
  70. 8.12.3 ViennaLab Diagnostics GmbH NGS Tumor Gene Analysis Software Revenue and Gross Margin (2021-2026)
  71. 8.12.4 ViennaLab Diagnostics GmbH NGS Tumor Gene Analysis Software Product Portfolio
  72. 8.12.5 ViennaLab Diagnostics GmbH Recent Developments
  73. 8.13 3D Medicines
  74. 8.13.1 3D Medicines Company Information
  75. 8.13.2 3D Medicines Business Overview
  76. 8.13.3 3D Medicines NGS Tumor Gene Analysis Software Revenue and Gross Margin (2021-2026)
  77. 8.13.4 3D Medicines NGS Tumor Gene Analysis Software Product Portfolio
  78. 8.13.5 3D Medicines Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst